APONTIS PHARMA AG

APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer

APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications

APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program

APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024

APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026

APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons